Sugi Predict

Sugi Predict / Compounds / SCHEMBL4475119

SCHEMBL4475119

SCHEMBL4475119

CCc1ccc(C(=O)NCC(F)(F)F)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 5/20 0.64
▸ POLB P06746 2/20 0.64
▸ PLK1 P53350 1/20 0.58
▸ ACACB O00763 1/20 0.53
▸ ALDH1A1 P00352 5/20 0.50
▸ TDP1 Q9NUW8 1/20 0.50
▸ GAA P10253 4/20 0.49
▸ HPGD P15428 1/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.49
▸ TAS1R3 Q7RTX0 1/20 0.49
▸ TAS1R1 Q7RTX1 1/20 0.49
▸ TAOK1 Q7L7X3 1/20 0.48
▸ TAOK3 Q9H2K8 1/20 0.48
▸ MAPK1 P28482 1/20 0.48
▸ NLRP1 Q9C000 1/20 0.48
▸ EPHX2 P34913 1/20 0.47
▸ NR1H4 Q96RI1 1/20 0.47
▸ NPC1 O15118 2/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ LSS P48449 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20180397 0.87 PLK1 (0.60) LMNAPOLBPLK1ACACBALDH1A1
SCHEMBL12388322 0.84 PLK1 (0.59) LMNAPOLBPLK1ALDH1A1TDP1
SCHEMBL27947108 0.84 EPHX2 (0.55) LMNAPOLBACACBALDH1A1SMN1; SMN2
SCHEMBL506515 0.83 HDAC3 (0.58) LMNAPOLBACACBALDH1A1SMN1; SMN2
SCHEMBL397853 0.82 LMNA (0.56) LMNAPOLBACACBALDH1A1TDP1
SCHEMBL1405105 0.81 ACACB (0.52) LMNAPOLBPLK1ACACBALDH1A1
SCHEMBL13483863 0.81 RAB9A (0.57) LMNAHPGDSMN1; SMN2MAPK1EPHX2
SCHEMBL23116863 0.80 GFER (0.53) LMNAACACBALDH1A1GAASMN1; SMN2
SCHEMBL12188582 0.80 EPHX2 (0.50) ACACBALDH1A1GAAEPHX2NR1H4
SCHEMBL4187911 0.80 CES2 (0.55) EPHX2LSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12018048-B2 Anthelmintic depsipeptide compounds Boehringer Ingelheim Animal Health USA Inc. (US) 2024-06-25 — — US disclosed
US-11382949-B2 Anthelmintic depsipeptide compounds Boehringer Ingelheim Animal Health USA Inc. (US) 2022-07-12 — — US disclosed
US-20220098241-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS Boehringer Ingelheim Animal Health USA Inc. (US) 2022-03-31 — — US disclosed
US-20200354408-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS Boehringer Ingelheim Animal Health USA Inc. (US) 2020-11-12 — — US disclosed
US-10793604-B2 Anthelmintic depsipeptide compounds Boehringer Ingelheim Animal Health USA Inc. (US) 2020-10-06 — — US disclosed
US-20190307838-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS Boehringer Ingelheim Animal Health USA Inc. (US) 2019-10-10 — — US disclosed
US-10344056-B2 Anthelmintic depsipeptide compounds Boehringer Ingelheim Animal Health USA Inc. (US) 2019-07-09 — — US disclosed
US-20170233438-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS MERIAL INC. (US) 2017-08-17 — — US disclosed
US-8680090-B2 Sulfonyl containing benzothiazole inhibitors of endothelial lipase BRISTOL-MYERS SQUIBB COMPANY (US) 2014-03-25 — — US disclosed
US-20120108566-A1 NICOTINAMIDES AS JAK KINASE MODULATORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-05-03 — — US disclosed
US-20090054472-A1 Pyrazolopyrimidine Derivatives or Pharmaceutically Acceptable Salts Thereof TEIJIN PHARMA LIMITED (JP) 2009-02-26 — — US disclosed
US-7473694-B2 Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof TEIJIN PHARMA LIMITED (JP) 2009-01-06 — — US disclosed
US-20070173519-A1 Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof TEIJIN PHARMA LIMITED 2007-07-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10344056-B2 Anthelmintic depsipeptide compounds VIP, PREP, DNPEP LMNA 2969/4885POLB 3608/4885PLK1 1283/4885
US-20090054472-A1 Pyrazolopyrimidine Derivatives or Pharmaceutically Acceptable Salts Thereof MAPKAPK2, MAPKAPK5, MAPKAPK3 LMNA 4673/4885POLB 4136/4885PLK1 324/4885
US-12018048-B2 Anthelmintic depsipeptide compounds VIP, DNPEP, DPEP1 LMNA 2297/4885POLB 2857/4885PLK1 1818/4885
US-11382949-B2 Anthelmintic depsipeptide compounds ENPP2, ROCK2, RRP12 LMNA 3787/4885POLB 4174/4885PLK1 2755/4885
US-20070173519-A1 Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof MAPKAPK2, MAPKAPK5, MAPKAPK3 LMNA 4673/4885POLB 4136/4885PLK1 324/4885
US-20170233438-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS VIP, PREP, DNPEP LMNA 2969/4885POLB 3608/4885PLK1 1283/4885
US-10793604-B2 Anthelmintic depsipeptide compounds VIP, PREP, DNPEP LMNA 2796/4885POLB 3257/4885PLK1 1135/4885
US-20220098241-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS VIP, PREP, DNPEP LMNA 2969/4885POLB 3608/4885PLK1 1283/4885
US-20190307838-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS ENPP2, ROCK2, RRP12 LMNA 3787/4885POLB 4174/4885PLK1 2755/4885
US-20120108566-A1 NICOTINAMIDES AS JAK KINASE MODULATORS JAK2, JAK1, NADK LMNA 2451/4885POLB 2890/4885PLK1 641/4885
US-20200354408-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS VIP, PREP, DNPEP LMNA 2796/4885POLB 3257/4885PLK1 1135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.